101
|
Ge Z, Pan C, Shu X, Pan W, Zhou D, Li W, Chen H, Wei L, Ge J. P916The effect of a novel, user-friendly, transcatheter edge-to-edge mitral valve repair device in a porcine model of mitral regurgitation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Objective
A new technique has been devised to treat mitral regurgitation (MR) through the transapical route by replicating the edge-to-edge repair surgery. This system encompasses an easy-to-use leaflet clamp and a smaller-sized delivery system (14F–16F). We aimed to evaluate the effectiveness of this device in a porcine model of acute MR.
Methods
Acute MR was induced in 36 anesthetized porcine subjects by severing the major chordae supporting the corresponding segment of the leaflet. This device was then transapically implanted on the prolapsing segment under 3D epicardial echocardiographic guidance. All of the animals were killed 30 days after the procedure to verify the proper location of the implanted devices.
Results
Cutting the major chordae induced an eccentric MR jet (MR grade: 3+, 27.8%/4+, 72.2%) in all of the animals. Every single pig was then successfully implanted with one clamp. The duration of catheterization ranged from 18 to 40 minutes. Overt MR reduction was observed following the procedure through echocardiography; residual MR was mild in 8 cases, trivial in 19 cases, and absent in 9 cases. In terms of hemodynamic parameters, the mean and maximum mitral valve pressure gradients were increased significantly (p<0.01), but these values were less than 4 mmHg in all of the cases. Autopsy demonstrated that all but one device were precisely placed to clip the prolapsing segment of the mitral valve, and there was no evidence of thrombosis, thromboembolism or impairment of the cardiac structure.
Table 1. Changes in hemodynamic parameters, cardiac size, and functional parameters after the procedure Preoperation Postoperation P value MR-maxA (mm2) 7.27±2.13 1.54±1.29 0.000 MVPG-max (mmHg) 1.95±0.47 3.66±0.62 0.000 MVPG-mean (mmHg) 0.87±0.31 1.7±0.28 0.000 LVEDD (mm) 46.08±2.85 46.44±3.53 0.239 LVESD (mm) 29.11±3.44 29.08±3.62 0.940 LVEF (%) 66.53±6.4 67.14±4.93 0.256 LAD (mm) 35.75±2.24 36.42±1.99 0.057 LAA (mm2) 12.95±2.22 12.64±1.55 0.301
Figure 1
Conclusions
Transapical implantation of the novel mitral valve repair device is effective and safe in reducing acutely induced MR in pigs; thus, suggesting that it has great potential for clinical benefit in patients with MR.
Acknowledgement/Funding
Shanghai Science and Technology Committee
Collapse
|
102
|
Piao JL, Jin YJ, Li ML, Zakki SA, Sun L, Feng QW, Zhou D, Kondo T, Cui ZG, Inadera H. Excessive Oxidative Stress in the Synergistic Effects of Shikonin on the Hyperthermia-Induced Apoptosis. Curr Mol Med 2019; 18:322-334. [PMID: 30360736 DOI: 10.2174/1566524018666181024161704] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 09/15/2018] [Accepted: 10/22/2018] [Indexed: 11/22/2022]
Abstract
BACKGROUND Hyperthermia (HT) has been used widely for cancer therapy, and the development of modern devices has made it more efficient. Shikonin (SHK) is a natural naphthoquinone derivative from a Chinese herb. Although the anticancer properties of SHK are evident, the underlying molecular mechanisms are not fully understood. OBJECTIVE In this study, the effects of combining low doses of SHK with mild HT were investigated in the U937 cell line. METHODS The cells were subjected to HT at 44°C for 10 min with or without SHK pretreatment, and parameters reflecting apoptosis, ROS generation and intracellular calcium elevation were evaluated by using DNA fragmentation, flow cytometry, and western blot analyses. RESULTS SHK 0.5 µM significantly enhanced HT-induced apoptosis as indicated by DNA fragmentation and caspase-3 activation with increased generation of ROS and elevation of intracellular calcium. The combined treatment also synergistically activated proapoptotic proteins and inactivated anti-apoptotic proteins. Furthermore, the phosphorylation of JNK and PKC- δ and the dephosphorylation of ERK and AKT were the upstream effects that may have compounded the induction of apoptosis. The modulatory effects of HT and SHK were abrogated with the employment of NAC and JNK-IN-8 by inactivating the MAPK pathway and cleavage of caspase-3. Intracellular calcium was also elevated and was found to be responsible for the induction of cell death evident by the DNA fragmentation with or without the employment of BAPTA-AM. CONCLUSION Conclusively, this study provides persuasive evidence that SHK in combination with HT is a propitious therapeutic way for augmentation of apoptosis and hence suggest a novel strategy for treating cancers.
Collapse
|
103
|
Acharya S, Adamová D, Adhya SP, Adler A, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Aiola S, Akindinov A, Al-Turany M, Alam SN, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Ali Y, Alici A, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andrews HA, Andronic A, Angeletti M, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Anwar R, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arratia M, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldisseri A, Ball M, Baral RC, Barbera R, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Batyunya B, Batzing PC, Bauri D, Bazo Alba JL, Bearden IG, Bedda C, Behera NK, Belikov I, Bellini F, Bellwied R, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Betev L, Bhasin A, Bhat IR, Bhatt H, Bhattacharjee B, Bianchi A, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boldizsár L, Bolozdynya A, Bombara M, Bonomi G, Bonora M, Borel H, Borissov A, Borri M, Bossi H, Botta E, Bourjau C, Bratrud L, Braun-Munzinger P, Bregant M, Broker TA, Broz M, Brucken EJ, Bruna E, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buncic P, Busch O, Buthelezi Z, Butt JB, Buxton JT, Caffarri D, Caliva A, Calvo Villar E, Camacho RS, Camerini P, Capon AA, Carnesecchi F, Castillo Castellanos J, Castro AJ, Casula EAR, Catalano F, Ceballos Sanchez C, Chakraborty P, Chandra S, Chang B, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Cormier TM, Corrales Morales Y, Cortese P, Cosentino MR, Costa F, Costanza S, Crkovská J, Crochet P, Cuautle E, Cunqueiro L, Dabrowski D, Dahms T, Dainese A, Damas FPA, Dani S, Danisch MC, Danu A, Das D, Das I, Das S, Dash A, Dash S, Dashi A, De S, De Caro A, de Cataldo G, de Conti C, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Souza RD, Deb S, Degenhardt HF, Deisting A, Deja KR, Deloff A, Delsanto S, Dhankher P, Di Bari D, Di Mauro A, Diaz RA, Dietel T, Dillenseger P, Ding Y, Divià R, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dordic O, Dubey AK, Dubla A, Dudi S, Duggal AK, Dukhishyam M, Dupieux P, Ehlers RJ, Elia D, Engel H, Epple E, Erazmus B, Erhardt F, Erokhin A, Ersdal MR, Espagnon B, Eulisse G, Eum J, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fantoni A, Fasel M, Fecchio P, Feldkamp L, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Foertsch S, Foka P, Fokin S, Fragiacomo E, Francisco A, Frankenfeld U, Fronze GG, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gal A, Galvan CD, Ganoti P, Garabatos C, Garcia-Solis E, Garg K, Gargiulo C, Garner K, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Gianotti P, Giubellino P, Giubilato P, Glässel P, Goméz Coral DM, Gomez Ramirez A, Gonzalez V, González-Zamora P, Gorbunov S, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Groettvik OS, Gronefeld JM, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guernane R, Guerzoni B, Guittiere M, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Habib MK, Hadjidakis C, Hamagaki H, Hamar G, Hamid M, Hamon JC, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hauer P, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hilden TE, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Horak D, Hornung S, Hosokawa R, Hristov P, Huang C, Hughes C, Huhn P, Humanic TJ, Hushnud H, Husova LA, Hussain N, Hussain SA, Hussain T, Hutter D, Hwang DS, Iddon JP, Ilkaev R, Inaba M, Ippolitov M, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadhav MB, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Jercic M, Jevons O, Jimenez Bustamante RT, Jin M, Jonas F, Jones PG, Jusko A, Kalinak P, Kalweit A, Kang JH, Kaplin V, Kar S, Karasu Uysal A, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kebschull U, Keidel R, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khan SA, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim B, Kim D, Kim DJ, Kim EJ, Kim H, Kim JS, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kim T, Kindra K, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein C, Klein J, Klein S, Klein-Bösing C, Klewin S, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Köhler MK, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konopka PJ, Koska L, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Krüger M, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar L, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kushpil S, Kvapil J, Kweon MJ, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Langoy R, Lapidus K, Lardeux A, Larionov P, Laudi E, Lavicka R, Lazareva T, Lea R, Leardini L, Lee S, Lehas F, Lehner S, Lehrbach J, Lemmon RC, León Monzón I, Lesser ED, Lettrich M, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lindal S, Lindenstruth V, Lindsay SW, Lippmann C, Lisa MA, Litichevskyi V, Liu A, Liu S, Ljunggren HM, Llope WJ, Lofnes IM, Loginov V, Loizides C, Loncar P, Lopez X, López Torres E, Luettig P, Luhder JR, Lunardon M, Luparello G, Lupi M, Maevskaya A, Mager M, Mahmood SM, Mahmoud T, Maire A, Majka RD, Malaev M, Malik QW, Malinina L, Mal'Kevich D, Malzacher P, Mamonov A, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Margutti J, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Martinez Pedreira M, Masciocchi S, Masera M, Masoni A, Massacrier L, Masson E, Mastroserio A, Mathis AM, Matuoka PFT, Matyja A, Mayer C, Mazzilli M, Mazzoni MA, Mechler AF, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Meres M, Mhlanga S, Miake Y, Micheletti L, Mieskolainen MM, Mihaylov DL, Mikhaylov K, Mischke A, Mishra AN, Miśkowiec D, Mitu CM, Mohammadi N, Mohanty AP, Mohanty B, Mohisin Khan M, Mondal M, Mondal MM, Mordasini C, Moreira De Godoy DA, Moreno LAP, Moretto S, Morreale A, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan JD, Munhoz MG, Münning K, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Naru MU, Nassirpour AF, Natal da Luz H, Nattrass C, Nayak R, Nayak TK, Nazarenko S, Negrao De Oliveira RA, Nellen L, Nesbo SV, Neskovic G, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Nomokonov P, Nooren G, Norman J, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onderwaater J, Oppedisano C, Orava R, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Pagano D, Paić G, Palni P, Pan J, Pandey AK, Panebianco S, Papikyan V, Pareek P, Park J, Parkkila JE, Parmar S, Passfeld A, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez GM, Perez Lezama E, Peskov V, Pestov Y, Petráček V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pimentel LODL, Pinazza O, Pinsky L, Pisano S, Piyarathna DB, Płoskoń M, Planinic M, Pliquett F, Pluta J, Pochybova S, Poghosyan MG, Polichtchouk B, Poljak N, Poonsawat W, Pop A, Poppenborg H, Porteboeuf-Houssais S, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Punin V, Puranapanda K, Putschke J, Quishpe RE, Ragoni S, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Raniwala R, Raniwala S, Räsänen SS, Rascanu BT, Rath R, Ratza V, Ravasenga I, Read KF, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Reshetin A, Revol JP, Reygers K, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rode SP, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rohr D, Röhrich D, Rokita PS, Ronchetti F, Rosas ED, Roslon K, Rosnet P, Rossi A, Rotondi A, Roukoutakis F, Roy A, Roy P, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Saarinen S, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Sambyal S, Samsonov V, Sandoval A, Sarkar A, Sarkar D, Sarkar N, Sarma P, Sarti VM, Sas MHP, Scapparone E, Schaefer B, Schambach J, Scheid HS, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Šefčík M, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Serradilla E, Sett P, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma M, Sharma N, Sheikh AI, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silvermyr D, Simatovic G, Simonetti G, Singh R, Singh R, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Snellman TW, Sochan J, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Stankus P, Steffanic PJ, Stenlund E, Stocco D, Storetvedt MM, Strmen P, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumowidagdo S, Suzuki K, Swain S, Szabo A, Szarka I, Tabassam U, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tarhini M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terrevoli C, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Torres SR, Tripathy S, Tripathy T, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tsuji T, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Utrobicic A, Vala M, Valle N, Vallero S, van der Kolk N, van Doremalen LVR, van Leeuwen M, Vande Vyvre P, Varga D, Varga-Kofarago M, Vargas A, Vargyas M, Varma R, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Veen AM, Vercellin E, Vergara Limón S, Vermunt L, Vernet R, Vértesi R, Vickovic L, Viinikainen J, Vilakazi Z, Villalobos Baillie O, Villatoro Tello A, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vrláková J, Wagner B, Watanabe Y, Weber M, Weber SG, Wegrzynek A, Weiser DF, Wenzel SC, Wessels JP, Westerhoff U, Whitehead AM, Widmann E, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Willsher E, Windelband B, Witt WE, Wu Y, Xu R, Yalcin S, Yamakawa K, Yang S, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yuan S, Yuncu A, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang X, Zhang Z, Zhao C, Zherebchevskii V, Zhigareva N, Zhou D, Zhou Y, Zhou Z, Zhu J, Zhu Y, Zichichi A, Zimmermann MB, Zinovjev G, Zurlo N. First Observation of an Attractive Interaction between a Proton and a Cascade Baryon. PHYSICAL REVIEW LETTERS 2019; 123:112002. [PMID: 31573229 DOI: 10.1103/physrevlett.123.112002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 06/28/2019] [Indexed: 06/10/2023]
Abstract
This Letter presents the first experimental observation of the attractive strong interaction between a proton and a multistrange baryon (hyperon) Ξ^{-}. The result is extracted from two-particle correlations of combined p-Ξ^{-}⊕p[over ¯]-Ξ[over ¯]^{+} pairs measured in p-Pb collisions at sqrt[s_{NN}]=5.02 TeV at the LHC with ALICE. The measured correlation function is compared with the prediction obtained assuming only an attractive Coulomb interaction and a standard deviation in the range [3.6, 5.3] is found. Since the measured p-Ξ^{-}⊕p[over ¯]-Ξ[over ¯]^{+} correlation is significantly enhanced with respect to the Coulomb prediction, the presence of an additional, strong, attractive interaction is evident. The data are compatible with recent lattice calculations by the HAL-QCD Collaboration, with a standard deviation in the range [1.8, 3.7]. The lattice potential predicts a shallow repulsive Ξ^{-} interaction within pure neutron matter and this implies stiffer equations of state for neutron-rich matter including hyperons. Implications of the strong interaction for the modeling of neutron stars are discussed.
Collapse
|
104
|
Zhou D, Zhang Y, Wang X. MON-PO413: Prediction of 1-Year Survival After Radical Gastrectomy in Gastric Cancer by Cachexia Score Assessed by CT. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32246-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
105
|
Gao X, Zhang L, Zhang Y, Liu H, Liu S, Zhou D, Wang X. MON-PO469: Effect of Home Enteral Nutrition in Malnourished Patients with Intestinal Failure/Intestinal Insufficiency. Clin Nutr 2019. [DOI: 10.1016/s0261-5614(19)32302-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
106
|
Li J, Das S, Zhou D, Al-Huniti N. Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. Clin Pharmacol Drug Dev 2019; 8:682-694. [PMID: 31044546 DOI: 10.1002/cpdd.673] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Accepted: 02/26/2019] [Indexed: 01/05/2023]
Abstract
Efficacy of ceftaroline fosamil, the prodrug of the active metabolite ceftaroline, was demonstrated in a phase 3 study of hospitalized Asian patients with Pneumonia Outcomes Research Team (PORT) risk class III-IV community-acquired pneumonia (NCT01371838). The objectives of the current analysis were to expand an existing ceftaroline and ceftaroline fosamil population pharmacokinetic (PK) model with data from this phase 3 study and a phase 1 study (NCT01458743) assessing ceftaroline PK in healthy Chinese volunteers and to evaluate the probability of PK/pharmacodynamic (PK/PD) target attainment (PTA) in Asian patients with community-acquired pneumonia (CAP) treated with ceftaroline fosamil. The ceftaroline plasma concentration-time course was simulated for 5000 Asian patients with CAP for different renal function subgroups using the final model. PTA was calculated for Streptococcus pneumoniae, Staphylococcus aureus, and non-extended-spectrum β-lactamase-producing Enterobacteriaceae. PTA was also evaluated for ceftaroline MIC90 values of isolates collected from Asia-Pacific surveillance studies (2012-2014) and for EUCAST and FDA/CLSI ceftaroline susceptibility break points. The final model reasonably described the ceftaroline PK. Race was not found to be a significant covariate impacting ceftaroline PK, suggesting similar ceftaroline PK in Asian and Western populations when corrected for body weight. High PTAs (90%-100%) were predicted for Asian patients with CAP treated with ceftaroline fosamil, covering MIC90 values of target CAP pathogens from the region. Similarly, >90% PTAs were predicted at EUCAST and FDA/CLSI clinical break points for these pathogens. These results support the use of the ceftaroline fosamil dosing regimens approved in Europe and the United States in Asian patients with PORT III-IV CAP.
Collapse
|
107
|
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Guo H, Wang A, Elstrom R, Huang J, Novotny W, Han L, Zhu J. ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.15_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
108
|
Zhou D, Zhang W, Su L, Liu L, Gao Y, Wang Q, Su H, Song Y, Zhang H, Shen J, Jing H, Wang S, Cen X, Liu H, Liu A, Li Z, Luo J, He J, Wang J. COMBINATION OF CHIDAMIDE WITH CHOEP REGIMEN IN PREVIOUSLY UNTREATED PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A PROSPECTIVE, MULTICENTER, SINGLE-ARM, PHASE 1B/2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.90_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
109
|
Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J. ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. Hematol Oncol 2019. [DOI: 10.1002/hon.55_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
110
|
Zhou D, Wang Z, Tu S, Chen S, Peng J, Tu K. Effects of cold plasma, UV‐C or aqueous ozone treatment on
Botrytis cinerea
and their potential application in preserving blueberry. J Appl Microbiol 2019; 127:175-185. [DOI: 10.1111/jam.14280] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2018] [Revised: 03/18/2019] [Accepted: 04/04/2019] [Indexed: 12/28/2022]
|
111
|
Zhou D, Podoll T, Xu Y, Moorthy G, Vishwanathan K, Ware J, Slatter JG, Al-Huniti N. Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 2019; 8:489-499. [PMID: 31044521 PMCID: PMC6656940 DOI: 10.1002/psp4.12408] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 03/22/2019] [Indexed: 12/18/2022]
Abstract
Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug–drug interactions (DDIs). The model indicated acalabrutinib would not perpetrate a CYP2C8 or CYP3A DDI with the sensitive CYP substrates rosiglitazone or midazolam, respectively. The model reasonably predicted clinically observed acalabrutinib DDI with the CYP3A perpetrators itraconazole (4.80‐fold vs. 5.21‐fold observed) and rifampicin (0.21‐fold vs. 0.23‐fold observed). An increase of two to threefold acalabrutinib area under the curve was predicted for coadministration with moderate CYP3A inhibitors. When both the parent drug and active metabolite (total active components) were considered, the magnitude of the CYP3A DDI was much less significant. PBPK dosing recommendations for DDIs should consider the magnitude of the parent drug excursion, relative to safe parent drug exposures, along with the excursion of total active components to best enable safe and adequate pharmacodynamic coverage.
Collapse
|
112
|
Zhou L, Tong X, Sharma P, Xu H, Al‐Huniti N, Zhou D. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study. Basic Clin Pharmacol Toxicol 2019; 125:100-107. [DOI: 10.1111/bcpt.13209] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/01/2019] [Indexed: 12/14/2022]
|
113
|
Ding GW, Ye SD, Hei FX, Lian QL, Pei XD, Bai JY, Zhou D, Yang Q, Hui S, Wang W, Tu AX, Pang L. [Sentinel surveillance for viral hepatitis C in China, 2016-2017]. ZHONGHUA LIU XING BING XUE ZA ZHI = ZHONGHUA LIUXINGBINGXUE ZAZHI 2019; 40:41-45. [PMID: 30669729 DOI: 10.3760/cma.j.issn.0254-6450.2019.01.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To understand the prevalence of hepatitis C virus (HCV) infection in 5 populations in China during 2016-2017 and provide evidence for the estimation of prevalence trend of hepatitis C and evaluation on the prevention and control effect. Methods: A total of 87 national sentinel surveillance sites for hepatitis C were set up in 31 provinces (autonomous regions and municipalities) of China to obtain the information about HCV infection prevalence in 5 populations, including volunteer blood donors, people receiving physical examination, patients receiving invasive diagnosis and treatment, patients receiving hemodialysis, and clients visiting family planning outpatient clinics. From April to June, 2016 and 2017, cross-sectional surveys were repeatedly conducted in the 5 populations and blood samples were collected from them for HCV antibody detection. Results: In 2016, 86 sentinel sites completed the surveillance (one sentinel site was not investigated), and 115 841 persons were surveyed. The overall HCV positive rate was 0.38% (442/115 841, 95%CI: 0.23%-0.53%). In 2017, all the 87 sentinel sites completed the surveillance, and 120 486 persons were surveyed. The overall HCV positive rate was 0.37% (449/120 486, 95%CI: 0.23%-0.52%). In 2016 and 2017, the anti-HCV positive rates were 4.46% (223/5 005, 95%CI: 2.18%-6.73%) and 4.39% (216/4 919, 95%CI: 2.29%-6.50%) respectively in hemodialysis patients, 0.85% (44/5 200, 95%CI: 0.27%-1.42%) and 0.70% (36/5 150, 95%CI: 0.15%-1.24%) respectively in patients receiving invasive diagnosis and treatment and remained to be ≤0.25% in volunteer blood donors, people receiving physical examination and clients visiting family planning outpatient clinics. Results for the comparison of the anti-HCV positive rates in the 5 populations indicated that the differences were significant (F=23.091, P<0.001 in 2016 and F=20.181, P<0.001 in 2017). Conclusions: Data from the sentinel surveillance of HCV infection on prevalence in China showed that the anti-HCV positive rates varied in the 5 populations during 2016-2017. The anti-HCV positive rate appeared the highest in the hemodialysis patients, followed by that in the patients receiving invasive diagnosis and treatment, and the prevalence of HCV infection in other 3 populations were at low levels.
Collapse
|
114
|
Zhou L, Higashimori M, Shen K, Zhang Z, Sheng J, Xu H, Horiuchi M, Ichikawa K, Al‐Huniti N, Zhou D. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies. Clin Pharmacol Ther 2019; 105:1303-1320. [DOI: 10.1002/cpt.1352] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Accepted: 12/20/2018] [Indexed: 12/25/2022]
|
115
|
Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al‐Huniti N, Tomkinson H, Xu H. Efficacy and Safety Exposure‐Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients. Clin Pharmacol Ther 2019; 105:1492-1500. [DOI: 10.1002/cpt.1338] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 11/07/2018] [Indexed: 01/05/2023]
|
116
|
Acharya S, Adamová D, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahn SU, Aiola S, Akindinov A, Al-Turany M, Alam SN, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfaro Molina R, Ali Y, Alici A, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Anaam MN, Andrei C, Andreou D, Andrews HA, Andronic A, Angeletti M, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Anwar R, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arnold OW, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldisseri A, Ball M, Baral RC, Barbano AM, Barbera R, Barile F, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Barth K, Bartsch E, Bastid N, Basu S, Batigne G, Batyunya B, Batzing PC, Bazo Alba JL, Bearden IG, Beck H, Bedda C, Behera NK, Belikov I, Bellini F, Bello Martinez H, Bellwied R, Beltran LGE, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Betev L, Bhaduri PP, Bhasin A, Bhat IR, Bhatt H, Bhattacharjee B, Bhom J, Bianchi A, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boldizsár L, Bombara M, Bonomi G, Bonora M, Borel H, Borissov A, Borri M, Botta E, Bourjau C, Bratrud L, Braun-Munzinger P, Bregant M, Broker TA, Broz M, Brucken EJ, Bruna E, Bruno GE, Budnikov D, Buesching H, Bufalino S, Buhler P, Buncic P, Busch O, Buthelezi Z, Butt JB, Buxton JT, Cabala J, Caffarri D, Caines H, Caliva A, Calvo Villar E, Camacho RS, Camerini P, Capon AA, Carena F, Carena W, Carnesecchi F, Castillo Castellanos J, Castro AJ, Casula EAR, Ceballos Sanchez C, Chandra S, Chang B, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Chung SU, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contreras JG, Cormier TM, Corrales Morales Y, Cortese P, Cosentino MR, Costa F, Costanza S, Crkovská J, Crochet P, Cuautle E, Cunqueiro L, Dahms T, Dainese A, Dani S, Danisch MC, Danu A, Das D, Das I, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Conti C, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Souza RD, Degenhardt HF, Deisting A, Deloff A, Delsanto S, Deplano C, Dhankher P, Di Bari D, Di Mauro A, Di Ruzza B, Diaz RA, Dietel T, Dillenseger P, Ding Y, Divià R, Djuvsland Ø, Dobrin A, Domenicis Gimenez D, Dönigus B, Dordic O, Doremalen LVR, Dubey AK, Dubla A, Ducroux L, Dudi S, Duggal AK, Dukhishyam M, Dupieux P, Ehlers RJ, Elia D, Endress E, Engel H, Epple E, Erazmus B, Erhardt F, Ersdal MR, Espagnon B, Eulisse G, Eum J, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fantoni A, Fasel M, Feldkamp L, Feliciello A, Feofilov G, Fernández Téllez A, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Figueredo MAS, Filchagin S, Finogeev D, Fionda FM, Fiorenza G, Flor F, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Francescon A, Francisco A, Frankenfeld U, Fronze GG, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gajdosova K, Gallio M, Galvan CD, Ganoti P, Garabatos C, Garcia-Solis E, Garg K, Gargiulo C, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Gianotti P, Giubellino P, Giubilato P, Glässel P, Goméz Coral DM, Gomez Ramirez A, Gonzalez V, González-Zamora P, Gorbunov S, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Gronefeld JM, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guernane R, Guerzoni B, Guittiere M, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Habib MK, Hadjidakis C, Hamagaki H, Hamar G, Hamid M, Hamon JC, Hannigan R, Haque MR, Harlenderova A, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Hernandez EG, Herrera Corral G, Herrmann F, Hetland KF, Hilden TE, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Horak D, Hornung S, Hosokawa R, Hota J, Hristov P, Huang C, Hughes C, Huhn P, Humanic TJ, Hushnud H, Hussain N, Hussain T, Hutter D, Hwang DS, Iddon JP, Iga Buitron SA, Ilkaev R, Inaba M, Ippolitov M, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadhav MB, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Jena C, Jercic M, Jevons O, Jimenez Bustamante RT, Jin M, Jones PG, Jusko A, Kalinak P, Kalweit A, Kang JH, Kaplin V, Kar S, Karasu Uysal A, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan AM, Khan S, Khan SA, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kielbowicz MM, Kileng B, Kim B, Kim D, Kim DJ, Kim EJ, Kim H, Kim JS, Kim J, Kim M, Kim S, Kim T, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Klay JL, Klein C, Klein J, Klein-Bösing C, Klewin S, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Kofarago M, Köhler MK, Kollegger T, Kondratyeva N, Kondratyuk E, Konevskikh A, Konopka PJ, Konyushikhin M, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krüger M, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar J, Kumar L, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kvapil J, Kweon MJ, Kwon Y, La Pointe SL, La Rocca P, Lai YS, Lakomov I, Langoy R, Lapidus K, Lardeux A, Larionov P, Laudi E, Lavicka R, Lea R, Leardini L, Lee S, Lehas F, Lehner S, Lehrbach J, Lemmon RC, León Monzón I, Lévai P, Li X, Li XL, Lien J, Lietava R, Lim B, Lindal S, Lindenstruth V, Lindsay SW, Lippmann C, Lisa MA, Litichevskyi V, Liu A, Ljunggren HM, Llope WJ, Lodato DF, Loginov V, Loizides C, Loncar P, Lopez X, López Torres E, Lowe A, Luettig P, Luhder JR, Lunardon M, Luparello G, Lupi M, Maevskaya A, Mager M, Mahmood SM, Maire A, Majka RD, Malaev M, Malik QW, Malinina L, Mal'Kevich D, Malzacher P, Mamonov A, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Margutti J, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JL, Martínez MI, Martínez García G, Martinez Pedreira M, Masciocchi S, Masera M, Masoni A, Massacrier L, Masson E, Mastroserio A, Mathis AM, Matuoka PFT, Matyja A, Mayer C, Mazzilli M, Mazzoni MA, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Mercado Pérez J, Meres M, Meza CS, Mhlanga S, Miake Y, Micheletti L, Mieskolainen MM, Mihaylov DL, Mikhaylov K, Mischke A, Mishra AN, Miśkowiec D, Mitra J, Mitu CM, Mohammadi N, Mohanty AP, Mohanty B, Mohisin Khan M, Moreira De Godoy DA, Moreno LAP, Moretto S, Morreale A, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mukherjee M, Mulligan JD, Munhoz MG, Münning K, Munoz MIA, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Narayan A, Naru MU, Nassirpour AF, Natal da Luz H, Nattrass C, Navarro SR, Nayak K, Nayak R, Nayak TK, Nazarenko S, Negrao De Oliveira RA, Nellen L, Nesbo SV, Neskovic G, Ng F, Nicassio M, Niedziela J, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Nomokonov P, Nooren G, Noris JCC, Norman J, Nyanin A, Nystrand J, Oh H, Ohlson A, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onderwaater J, Oppedisano C, Orava R, Oravec M, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Pagano D, Paić G, Palni P, Pan J, Pandey AK, Panebianco S, Papikyan V, Pareek P, Park J, Parkkila JE, Parmar S, Passfeld A, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez Lezama E, Peskov V, Pestov Y, Petráček V, Petrovici M, Petta C, Pezzi RP, Piano S, Pikna M, Pillot P, Pimentel LODL, Pinazza O, Pinsky L, Pisano S, Piyarathna DB, Płoskoń M, Planinic M, Pliquett F, Pluta J, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polichtchouk B, Poljak N, Poonsawat W, Pop A, Poppenborg H, Porteboeuf-Houssais S, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Punin V, Putschke J, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Raniwala R, Raniwala S, Räsänen SS, Rascanu BT, Ratza V, Ravasenga I, Read KF, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Reshetin A, Revol JP, Reygers K, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rode SP, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rohr D, Röhrich D, Rokita PS, Ronchetti F, Rosas ED, Roslon K, Rosnet P, Rossi A, Rotondi A, Roukoutakis F, Roy C, Roy P, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Saarinen S, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Saleh MA, Sambyal S, Samsonov V, Sandoval A, Sarkar A, Sarkar D, Sarkar N, Sarma P, Sas MHP, Scapparone E, Scarlassara F, Schaefer B, Scheid HS, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Šefčík M, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Serradilla E, Sett P, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma M, Sharma N, Sheikh AI, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Shtejer K, Sibiriak Y, Siddhanta S, Sielewicz KM, Siemiarczuk T, Silvermyr D, Simatovic G, Simonetti G, Singaraju R, Singh R, Singh R, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Snellman TW, Song J, Soramel F, Sorensen S, Sozzi F, Sputowska I, Stachel J, Stan I, Stankus P, Stenlund E, Stocco D, Storetvedt MM, Strmen P, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumowidagdo S, Suzuki K, Swain S, Szabo A, Szarka I, Tabassam U, Takahashi J, Tambave GJ, Tanaka N, Tarhini M, Tariq M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terrevoli C, Teyssier B, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Torres SR, Tripathy S, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzcinski TP, Trzeciak BA, Tsuji T, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Utrobicic A, Vala M, Van Hoorne JW, van Leeuwen M, Vande Vyvre P, Varga D, Vargas A, Vargyas M, Varma R, Vasileiou M, Vasiliev A, Vauthier A, Vázquez Doce O, Vechernin V, Veen AM, Vercellin E, Vergara Limón S, Vermunt L, Vernet R, Vértesi R, Vickovic L, Viinikainen J, Vilakazi Z, Villalobos Baillie O, Villatoro Tello A, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vranic D, Vrláková J, Wagner B, Wang H, Wang M, Watanabe Y, Weber M, Weber SG, Wegrzynek A, Weiser DF, Wenzel SC, Wessels JP, Westerhoff U, Whitehead AM, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Williams MCS, Willsher E, Windelband B, Witt WE, Xu R, Yalcin S, Yamakawa K, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang X, Zhang Y, Zhang Z, Zhao C, Zherebchevskii V, Zhigareva N, Zhou D, Zhou Y, Zhou Z, Zhu H, Zhu J, Zhu Y, Zichichi A, Zimmermann MB, Zinovjev G, Zmeskal J, Zou S. Azimuthal Anisotropy of Heavy-Flavor Decay Electrons in p-Pb Collisions at sqrt[s_{NN}]=5.02 TeV. PHYSICAL REVIEW LETTERS 2019; 122:072301. [PMID: 30848618 DOI: 10.1103/physrevlett.122.072301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 10/16/2018] [Indexed: 06/09/2023]
Abstract
Angular correlations between heavy-flavor decay electrons and charged particles at midrapidity (|η|<0.8) are measured in p-Pb collisions at sqrt[s_{NN}]=5.02 TeV. The analysis is carried out for the 0%-20% (high) and 60%-100% (low) multiplicity ranges. The jet contribution in the correlation distribution from high-multiplicity events is removed by subtracting the distribution from low-multiplicity events. An azimuthal modulation remains after removing the jet contribution, similar to previous observations in two-particle angular correlation measurements for light-flavor hadrons. A Fourier decomposition of the modulation results in a positive second-order coefficient (v_{2}) for heavy-flavor decay electrons in the transverse momentum interval 1.5<p_{T}<4 GeV/c in high-multiplicity events, with a significance larger than 5σ. The results are compared with those of charged particles at midrapidity and those of inclusive muons at forward rapidity. The v_{2} measurement of open heavy-flavor particles at midrapidity in small collision systems could provide crucial information to help interpret the anisotropies observed in such systems.
Collapse
|
117
|
Das S, Li J, Iaconis J, Zhou D, Stone GG, Yan JL, Melnick D. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections. J Antimicrob Chemother 2019; 74:425-431. [PMID: 30380060 PMCID: PMC6337900 DOI: 10.1093/jac/dky439] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2018] [Revised: 09/27/2018] [Accepted: 10/01/2018] [Indexed: 12/16/2022] Open
Abstract
Objectives To describe the pharmacokinetic/pharmacodynamic (PK/PD) modelling and microbiological data that were used to support the recent European approval of ceftaroline fosamil 600 mg q8h by 2 h intravenous (iv) infusion for patients with complicated skin and soft tissue infections (cSSTIs) caused by Staphylococcus aureus with ceftaroline MICs of 2 or 4 mg/L, and the associated EUCAST MIC breakpoint update for q8h dosing (intermediate = 2 mg/L and resistant >2 mg/L). Methods A population PK model for ceftaroline and ceftaroline fosamil was developed using PK data from 21 clinical studies. The final model was used to simulate PTA in patients with cSSTI receiving ceftaroline fosamil 600 mg q12h by 1 h iv infusion or 600 mg q8h by 2 h iv infusion. PTA was calculated by MIC for S. aureus PK/PD targets derived from preclinical studies (27% fT>MIC for stasis, 31% fT>MIC for 1 log10 kill and 35% fT>MIC for 2 log10 kill) and compared with S. aureus ceftaroline MIC distributions from a 2013 global surveillance study. Results The final population PK model based on 951 subjects adequately described ceftaroline and ceftaroline fosamil PK. High PTA (>90%) was predicted for the ceftaroline fosamil 600 mg q12h dosage regimen against S. aureus isolates with ceftaroline MICs ≤2 mg/L. Greater than 90% PTA was predicted for the ceftaroline fosamil 600 mg q8h dosage regimen against S. aureus with ceftaroline MICs ≤4 mg/L. Conclusions The approved ceftaroline fosamil dosage regimens for adults and adolescents with cSSTI achieve high PTA against S. aureus at the associated EUCAST breakpoints.
Collapse
|
118
|
Hlady RA, Sathyanarayan A, Thompson JJ, Zhou D, Wu Q, Pham K, Lee JH, Liu C, Robertson KD. Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma. Hepatology 2019; 69:639-652. [PMID: 30136421 PMCID: PMC6351162 DOI: 10.1002/hep.30211] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 08/03/2018] [Indexed: 12/20/2022]
Abstract
Disruption of epigenetic mechanisms has been intimately linked to the etiology of human cancer. Understanding how these epigenetic mechanisms (including DNA methylation [5mC], hydroxymethylation [5hmC], and histone post-translational modifications) work in concert to drive cancer initiation and progression remains unknown. Hepatocellular carcinoma (HCC) is increasing in frequency in Western countries but lacks efficacious treatments. The epigenome of HCC remains understudied. To better understand the epigenetic underpinnings of HCC, we performed a genome-wide assessment of 5mC, 5hmC, four histone modifications linked to promoter/enhancer function (H3K4me1, H3K27ac, H3K4me3, and H3K27me3), and transcription across normal, cirrhotic, and HCC liver tissue. Implementation of bioinformatic strategies integrated these epigenetic marks with each other and with transcription to provide a comprehensive epigenetic profile of how and when the liver epigenome is perturbed during progression to HCC. Our data demonstrate significant deregulation of epigenetic regulators combined with disruptions in the epigenome hallmarked by profound loss of 5hmC, locus-specific gains in 5mC and 5hmC, and markedly altered histone modification profiles, particularly remodeling of enhancers. Data integration demonstrates that these marks collaborate to influence transcription (e.g., hyper-5hmC in HCC-gained active enhancers is linked to elevated expression) of genes regulating HCC proliferation. Two such putative epigenetic driver loci identified through our integrative approach, COMT and FMO3, increase apoptosis and decrease cell viability in liver-derived cancer cell lines when ectopically re-expressed. Conclusion: Altogether, integration of multiple epigenetic parameters is a powerful tool for identifying epigenetically regulated drivers of HCC and elucidating how epigenome deregulation contributes to liver disease and HCC.
Collapse
|
119
|
Xu H, Tong X, Mugundu G, Scott ML, Cook C, Arfvidsson C, Pease E, Zhou D, Lyne P, Al-Huniti N. Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch. J Pharmacokinet Pharmacodyn 2019; 46:65-74. [PMID: 30661177 DOI: 10.1007/s10928-019-09619-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Accepted: 01/11/2019] [Indexed: 02/07/2023]
Abstract
Danvatirsen is a Generation 2.5 antisense oligonucleotide under clinical development. Population PK modelling was conducted using data from 3 available danvatirsen Phase I/II studies in oncology patients to investigate the impact of flat dosing on exposure compared to ideal body weight-based dosing. A total of 126 patients who received danvatirsen doses ranging from 1 to 4 mg/kg as monotherapy or in combination with durvalumab, most at 3 mg/kg (n = 70), was used in the danvatirsen population PK analysis. A 2-compartment model with linear elimination described the data well. Covariate analysis revealed ideal body weight was not a significant covariate on the PK of danvatirsen; nor was age, sex or race. The model-based simulation suggested that steady state weekly AUC and Cmax were very similar between 3 mg/kg and 200 mg flat dosing (geometric mean of AUC: 62.5 vs. 63.4 mg h/L and Cmax: 26.2 vs. 26.5 mg/L for two dose groups) with slightly less overall between-subject variability in the flat dosing regimen. The switch to flat dosing was approved by multiple regulatory agencies, including FDA, EMA, PMDA and ANSM. Several ongoing studies have been evaluating flat dosing. Interim analysis from an ongoing study (D5660C00016, NCT03421353) has shown the observed steady state concentration from 200 mg flat dose is in agreement with the model predictions. The population PK model could be further utilized in subsequent exposure-response efficacy and safety modelling.
Collapse
|
120
|
Zhou D, Lu L, Luo Y, Chen F, He JR, Dong MW. Structures, Photoluminescence, and Photocatalytic Properties of Two New Coordination Polymers based on 4-nitroimidazolate. RUSS J COORD CHEM+ 2019. [DOI: 10.1134/s1070328418120126] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
121
|
Wu F, Zhou D, Shen G, Cui Y, Lv Q, Wei F. Association of VDR and OPG gene polymorphism with osteoporosis risk in Chinese postmenopausal women. Climacteric 2019; 22:208-212. [PMID: 30624097 DOI: 10.1080/13697137.2018.1554643] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
AIMS The underlying mechanisms of vitamin D receptor (VDR) and osteoprotegerin (OPG) genetic variation associated with bone mineral density and osteoporosis remain uncertain. This study aimed to investigate the association of VDR and OPG gene polymorphism as well as gene-gene interaction and their haplotype combination with the risk of osteoporosis. METHODS Polymerase chain reaction restriction fragment length polymorphism was carried out for single nucleotide polymorphism (SNP) detection. Generalized multifactor dimension reduction (GMDR) is used to identify the interaction. SHEsis software evaluated the haplotype and logistic regression was performed to assess the association between the SNPs within the VDR and OPG genes and osteoporosis. RESULTS The risk of osteoporosis in the VDR-rs2228570 polymorphism T-allele carriers was significantly higher than that in CC (CT/TT versus CC) individuals (adjusted odds ratio [OR] [95% confidence interval (CI)] = 1.76 [1.33-2.22]). The risk of osteoporosis was also higher in the G-allele carrier of the OPG-rs3102735 polymorphism than in individuals with the AA genotype (AG/GG vs. AA) (adjusted OR [95% CI] = 1.65 [1.27-2.14]). However, after adjusting for sex, age, and waist circumference covariates, no significant association of VDR-rs17879735 and OPG-rs2073618 with the osteoporosis risk was revealed. The GMDR method identified that gene-gene interactions were significant, but not for gene/AO interaction. Haplotypes were analyzed with SHEsis software. We did not detect a high-risk haplotype combination associated with osteoporosis. CONCLUSIONS Both VDR-rs2228570-T and OPG-rs3102735-G and their interactions are related to the increased risk of osteoporosis.
Collapse
|
122
|
Zhou D, Yang Y, Tang ZH, Gong W, Wang JD, Quan ZW. [History, current situation and bottleneck of the diagnosis and treatment system of hepatic hilar cholangiocarcinoma in Japan]. ZHONGHUA WAI KE ZA ZHI [CHINESE JOURNAL OF SURGERY] 2019; 57:6-9. [PMID: 30612386 DOI: 10.3760/cma.j.issn.0529-5815.2019.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Hilar cholangiocarcinoma is one of the most difficult malignant tumors to treat in the biliary system. In Japan, 5-year survival rate of the disease has increased from 32.5% to 67.1% during the past 30 years. The impressive progress reflects the solid efforts in preoperative endoscopic diagnosis, innovation in surgery such as PTPE as well as hepato-pancreatoduodenectomy and perioperative treatment including replacement of the bile and synbiotic treatment, which have finally formed a set of standardized diagnosis and treatment systems. The present review intends to report the history, current status and remaining bottlenecks of the diagnosis and treatment system of hilar cholangiocarcinoma in Japan as follows.
Collapse
|
123
|
Ryoo BY, Ren Z, Kim TY, Pan H, Rau KM, Choi H, Park JW, Kim J, Yen CJ, Kim BH, Zhou D, Straub J, Zhao C, Qin S. Phase II trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
124
|
Zhou D, Ouyang Q, Xiong M, Zhang Y. Crohn's disease with positive Ziehl-Neelsen stain: Three case reports. Niger J Clin Pract 2018; 21:1387-1390. [PMID: 30297577 DOI: 10.4103/njcp.njcp_31_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Because of the similarity of the clinical symptoms, endoscopic, and pathological features, the differential diagnosis between Crohn's disease (CD) and intestinal tuberculosis (ITB) remains difficult, especially in a high-incidence area of tuberculosis (TB). Here we reported three patients with positive Ziehl-Neelsen stain in endoscopic mucosal biopsy specimens. They had a poor response to anti-TB therapy but a good response to immunosuppresses, infliximab, or surgery, and were finally diagnosed as CD. It was not clear that they were CD concomitant with mycobacteria infection or CD induced by mycobacteria infection. Further studies including more clinical cases and related animal models are needed. Our cases highlight the importance of considering the presence of CD in patients with positive Ziehl-Neelsen stain, which were failure to respond to anti-TB treatment.
Collapse
|
125
|
Tang WW, An HX, Zhou D, Cai MQ, Zeng R, Lv XJ, Chen LL, Ye F, Zhang Y. Correlation between ctDNA methylation and CEA in colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
126
|
Ryoo BY, Ren Z, Kim TY, Pan H, Rau KM, Choi H, Park JW, Kim J, Yen CJ, Kim BH, Zhou D, Straub J, Zhao C, Qin S. Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
127
|
Li J, Lovern M, Green ML, Chiu J, Zhou D, Comisar C, Xiong Y, Hing J, MacPherson M, Wright JG, Riccobene T, Carrothers TJ, Das S. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clin Transl Sci 2018; 12:151-163. [PMID: 30221827 PMCID: PMC6440567 DOI: 10.1111/cts.12585] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Accepted: 08/11/2018] [Indexed: 02/06/2023] Open
Abstract
Ceftazidime‐avibactam is a novel β‐lactam/β‐lactamase inhibitor combination for the treatment of serious infections caused by resistant gram‐negative pathogens. Population pharmacokinetic (PopPK) models were built to incorporate pharmacokinetic (PK) data from five phase III trials in patients with complicated intra‐abdominal infection (cIAI), complicated urinary tract infection (cUTI), or nosocomial (including ventilator‐associated) pneumonia. Ceftazidime and avibactam pharmacokinetics were well‐described by two‐compartment disposition models, with creatinine clearance (CrCL) the key covariate determining clearance variability. Steady‐state ceftazidime and avibactam exposure for most patient subgroups differed by ≤ 20% vs. healthy volunteers. Probability of PK/pharmacodynamic (PD) target attainment (free plasma ceftazidime > 8 mg/L and avibactam > 1 mg/L for ≥ 50% of dosing interval) was ≥ 94.9% in simulations for all patient subgroups, including indication and renal function categories. No exposure‐microbiological response relationship was identified because target exposures were achieved in almost all patients. These modeling results support the approved ceftazidime‐avibactam dosage regimens (2000‐500 mg every 8 hours, adjusted for CrCL ≤ 50 mL/min).
Collapse
|
128
|
Tang Y, An D, Xiao Y, Niu R, Tong X, Liu W, Zhao L, Gong Q, Zhou D. Cortical thinning in epilepsy patients with postictal generalized electroencephalography suppression. Eur J Neurol 2018; 26:191-197. [PMID: 30153362 DOI: 10.1111/ene.13794] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Accepted: 08/17/2018] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND PURPOSE The aim was to investigate the brain microstructural abnormalities in epilepsy patients with postictal generalized electroencephalographic suppression (PGES) using a cortical surface-based analysis. METHODS According to the video-electroencephalography records of epilepsy patients with generalized convulsive seizures, 30 patients with PGES (PGES+) and 21 patients without PGES (PGES-) were recruited. High-resolution T1-weighted images were acquired from each patient and 30 matched healthy control subjects. Cortical thickness was compared amongst the three groups using FreeSurfer software. RESULTS Patients with PGES showed reduced cortical thickness in the right paracentral lobule, inferior parietal lobule, supramarginal gyrus and middle temporal lobe compared with patients without PGES. In relation to healthy control subjects, the PGES+ group presented reduced cortical thickness in the right superior parietal lobule and supramarginal gyrus, whilst the PGES- group presented reduced cortical thickness in the left precuneus, precentral gyrus, lateral occipital gyrus, parahippocampal gyrus, superior parietal lobule and right caudal middle frontal gyrus. CONCLUSIONS Patients with PGES exhibited characteristic brain microstructural abnormalities, corroborating the PGES mechanisms at the brain level. The right-sided predominance of the detected PGES-related cortical thinning was the same as that of sudden unexpected death in epilepsy (SUDEP) cases and patients at high risk for SUDEP, implying that PGES and SUDEP may share a common abnormal brain substrate that is involved in the pathophysiology of these conditions.
Collapse
|
129
|
Xiao X, Zhang C, Grigoroiu-Serbanescu M, Wang L, Li L, Zhou D, Yuan TF, Wang C, Chang H, Wu Y, Li Y, Wu DD, Yao YG, Li M. The cAMP responsive element-binding (CREB)-1 gene increases risk of major psychiatric disorders. Mol Psychiatry 2018; 23:1957-1967. [PMID: 29158582 DOI: 10.1038/mp.2017.243] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Revised: 08/25/2017] [Accepted: 09/14/2017] [Indexed: 12/11/2022]
Abstract
Bipolar disorder (BPD), schizophrenia (SCZ) and unipolar major depressive disorder (MDD) are primary psychiatric disorders sharing substantial genetic risk factors. We previously reported that two single-nucleotide polymorphisms (SNPs) rs2709370 and rs6785 in the cAMP responsive element-binding (CREB)-1 gene (CREB1) were associated with the risk of BPD and abnormal hippocampal function in populations of European ancestry. In the present study, we further expanded our analyses of rs2709370 and rs6785 in multiple BPD, SCZ and MDD data sets, including the published Psychiatric Genomics Consortium (PGC) genome-wide association study, the samples used in our previous CREB1 study, and six additional cohorts (three new BPD samples, two new SCZ samples and one new MDD sample). Although the associations of both CREB1 SNPs with each illness were not replicated in the new cohorts (BPD analysis in 871 cases and 1089 controls (rs2709370, P=0.0611; rs6785, P=0.0544); SCZ analysis in 1273 cases and 1072 controls (rs2709370, P=0.230; rs6785, P=0.661); and MDD analysis in 129 cases and 100 controls (rs2709370, P=0.114; rs6785, P=0.188)), an overall meta-analysis of all included samples suggested that both SNPs were significantly associated with increased risk of BPD (11 105 cases and 51 331 controls; rs2709370, P=2.33 × 10-4; rs6785, P=6.33 × 10-5), SCZ (34 913 cases and 44 528 controls; rs2709370, P=3.96 × 10-5; rs6785, P=2.44 × 10-5) and MDD (9369 cases and 9619 controls; rs2709370, P=0.0144; rs6785, P=0.0314), with the same direction of allelic effects across diagnostic categories. We then examined the impact of diagnostic status on CREB1 mRNA expression using data obtained from independent brain tissue samples, and observed that the mRNA expression of CREB1 was significantly downregulated in psychiatric patients compared with healthy controls. The protein-protein interaction analyses showed that the protein encoded by CREB1 directly interacted with several risk genes of psychiatric disorders identified by GWAS. In conclusion, the current study suggests that CREB1 might be a common risk gene for major psychiatric disorders, and further investigations are necessary.
Collapse
|
130
|
Tong X, Xu H, Carlile DJ, Tomkinson H, Al‐Huniti N, Zhou D. Population Pharmacokinetic and Exposure‐Response Analysis of Selumetinib and Its N‐desmethyl Metabolite in Patients With Non‐Small Cell Lung Cancer. J Clin Pharmacol 2018; 59:112-122. [DOI: 10.1002/jcph.1295] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 07/06/2018] [Indexed: 11/05/2022]
|
131
|
Pilla Reddy V, Bui K, Scarfe G, Zhou D, Learoyd M. Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations. Clin Pharmacol Ther 2018; 105:229-241. [PMID: 29717476 PMCID: PMC6585620 DOI: 10.1002/cpt.1103] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Accepted: 04/21/2018] [Indexed: 12/13/2022]
Abstract
We report physiologically based pharmacokinetic-modeling analyses to determine olaparib (tablet or capsule) drug-drug interactions (DDIs). Verified DDI simulations provided dose recommendations for olaparib coadministration with clinically relevant CYP3A4 modulators to eliminate potential risk to patient safety or olaparib efficacy. When olaparib is given with strong/moderate CYP3A inhibitors, the dose should be reduced to 100/150 mg b.i.d. (tablet), and 150/200 mg b.i.d. (capsule). Olaparib administration is not recommended with strong/moderate CYP3A inducers. No dose reductions are required with weak CYP3A inhibitors/inducers. Olaparib was shown to be a weak inhibitor of CYP3A (1.6-fold increase in exposure of a sensitive CYP3A probe) and to have no effect on P-glycoprotein or UGT1A1 substrates. Finally, this model was used to simulate exposure in scenarios where clinical data of olaparib are lacking, such as severe renal or hepatic impairment populations, and provided initial dosing recommendations in pediatric patients.
Collapse
|
132
|
Xie M, Li L, Zhu L, Zhou D, Yang X, Sun J, Zhu J, Zhu M, Zheng Y, Xie W, Ye X. An effective diagnostic index for lymphoma-associated hemophagocytic syndrome. QJM 2018; 111:541-547. [PMID: 29800321 DOI: 10.1093/qjmed/hcy103] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Revised: 04/22/2018] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND Lymphoma-associated hemophagocytic syndrome (LAHS) is a highly fatal immune disorder. Poor prognosis is partly attributed to under diagnosis or delayed diagnosis. AIM Early identification of LAHS patients based on the laboratory findings could improve the outcomes. DESIGN Retrospective observational cross-sectional study. METHODS From January 2011 to June 2016, 282 adult patients with hemophagocytosis in bone marrow were enrolled, and 114 hemophagocytic lymphohistiocytosis (HLH) patients with definite underlying cause were finally included for analysis. The HLH patients were further divided into LAHS (76 out of 114) and non-malignancy-associated HLH (38 out of 114) groups. RESULTS Compared to non-malignancy-associated HLH, LAHS patients had significantly elevated lactate dehydrogenase (LDH) levels, increased thickness of spleen, higher proportion of patients with lymphadenopathy and significantly decreased peripheral blood cell count. In multivariate logistic regression model analysis, thickness of spleen ≥5 cm (OR = 17.9, 95%CI 1.35-236.6; P = 0.028), IL-6 level ≥55.1 pg/ml (OR = 12.01, 95%CI 1.03-138.9; P = 0.047) and IL-10 level ≥425.9 pg/ml (OR = 51.18, 95%CI 2.53-1035.1; P = 0.010) were independent predictors of LAHS diagnosis. Based on the regression parameters, we established a diagnostic index with weighted risk scores of 1 assigned to thickness of spleen and IL-6 level respectively, and a score of 3 assigned to IL-10 level. A diagnostic index ≥ 2 points had the best AUC value (0.889) with 84.2% of sensitivity and 93.7% of specificity for predicting LAHS. CONCLUSIONS LAHS can be considered when HLH patients have a diagnostic index ≥2 points, so actively looking for evidence of lymphoma and effective chemotherapy may be necessary.
Collapse
|
133
|
Tong X, Dunyak J, Zhou D, Carlile D, Tomkinson H, Helmlinger G, Al-Huniti N, Xu H. Abstract 4760: Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-4760] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Tumor size dynamics and survival are traditionally analyzed in a 2-stage approach, without consideration of joint dependencies. The objective of this analysis was to develop a joint model which associates tumor size dynamics and progression-free survival (PFS), to predict time-to-progression. Methods: Phase 2 trial data from selumetinib (AZD6244; ARRY-142886, MEK inhibitor), in NSCLC patients (SELECT-2; NCT01750281) were used to develop a joint model for tumor size dynamics and PFS. The analysis was performed using JM package in R. Treatment arm, KRAS mutation and WHO performance status were evaluated as covariates. Model was evaluated by survival estimation based on early time (e.g., first 3 months) tumor size data. The final joint model based on SELECT-2 data was then used to predict PFS of selumetinib in SELECT-1 (NCT01933932) phase 3 trial. Results: The joint model developed on SELECT-2 data identified a significant association (p value <0.001) between the slope of the longitudinal tumor dynamic and PFS. WHO performance status was identified to be the only significant covariate. Furthermore, the model built on phase 2 data adequately predicted PFS of the SELECT-1 data, using SELECT-1 tumor size data within 4 months of treatment. Prediction confirmed no significant difference in PFS between active treatment arm and chemotherapy arm in SELECT-1 trial. Conclusions: Using selumetinib as an example, we showed that joint modeling of tumor size dynamics and PFS may provide a novel quantitative tool to predict long-term outcome in NSCLC based on early tumor size measurements.
Citation Format: Xiao Tong, James Dunyak, Diansong Zhou, David Carlile, Helen Tomkinson, Gabriel Helmlinger, Nidal Al-Huniti, Hongmei Xu. Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4760.
Collapse
|
134
|
Schmitt F, Aurlien H, Brøgger J, Hirsch L, Schomer D, Trinka E, Pressler R, Wennberg R, Visser G, Eisermann M, Diehl B, Lesser R, Kaplan P, The Tich S, Lee J, Martins-da-Silva A, Stefan H, Neufeld M, Rubboli G, Fabricius M, Gardella E, Terney D, Meritam P, Eichele T, Asano E, Cox F, van Emde Boas W, Mameniskiene R, Marusic P, Zárubová J, Rosén I, Fuglsang-Frederiksen A, Ikeda A, MacDonald D, Terada K, Ugawa Y, Zhou D, Herman S, Beniczky S. Standardisierter Computer-basiert-organisierter Report des EEG (SCORE) – Eine strukturierende Form der EEG-Befundung. KLIN NEUROPHYSIOL 2018. [DOI: 10.1055/s-0043-125304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
ZusammenfassungEine 2013 von der „International Federation of Clinical Neurophysiology“ gegründete Taskforce hat eine international konsensfähige EEG-Terminologie entwickelt. Im Folgenden soll das Resultat – die 2. Version des Standardized Computer-based Organized Reporting of EEG (SCORE) - vorgestellt werden. Die Terminologie wurde im Rahmen eines Softwarepaketes (SCORE-EEG) in der klinischen Praxis an über 12.000 EEGs getestet. Die Auswahl der Begriffe ist kontextabhängig: die initiale Auswahl bestimmt, welche weiteren Auswahlmöglichkeiten zur Verfügung stehen. Im Verlauf wird automatisch ein Befund erstellt und dessen Einzelmerkmale in eine Datenbank eingespeist. SCORE verfügt über Module spezifisch für die Befundung epileptischer Anfälle, sowie charakteristischer neonataler und intensivmedizinische EEG-Merkmale. SCORE ist nicht nur ein nützliches Werkzeug im ambulanten, klinischen und wissenschaftlichen Setting, es erleichtert auch Qualitätssicherung, Datenaustausch und die EEG-Aus und Weiterbildung.
Collapse
|
135
|
Tong X, Zhou D, Savage A, Mullen JA, Li Y, Taylor W, Li J, Al-Huniti N, Xu H. Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System Atrophy. J Clin Pharmacol 2018; 58:1452-1460. [PMID: 29873817 DOI: 10.1002/jcph.1134] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 03/14/2018] [Indexed: 12/11/2022]
Abstract
AZD3241 is a potent and selective myeloperoxidase inhibitor potentially for the treatment of a number of neurodegenerative disorders, including multiple system atrophy (MSA). The objectives of this work were to develop a population pharmacokinetic (PopPK) model for AZD3241 and to investigate the correlation between AZD3241 exposure and myeloperoxidase inhibition. The PopPK model was developed using AZD3241 data from one phase 1 study in healthy subjects and one phase 2 study in patients with MSA. A one-compartment model incorporating a gallbladder compartment for enterohepatic circulation, sequential zero-first order absorption, and first-order elimination adequately described the AZD3241 concentration profiles. The apparent clearance and central volume of distribution were 63.1 L/h (interindividual variability: 34.8%) and 121.9 L (interindividual variability: 44.0%), respectively. The enterohepatic circulation model reasonably captured the second peak of AZD3241, and high-fat food increased the absorption rate by 69%. A linear regression model was applied to describe the relationship between AZD3241 exposure and percentage change from baseline in myeloperoxidase-specific activity. The developed PopPK model was consistent with known pharmacokinetic characteristics of AZD3241. This model can be used to estimate AZD3241 exposure in patients with MSA and could be applied to future pharmacokinetic-pharmacodynamic analyses of AZD3241 in clinical development.
Collapse
|
136
|
Wind O, Zhou D, Zippin J. 1235 Expression pattern of melanosomal proteins following inhibition of soluble adenylyl cyclase. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
137
|
O'Keeffe Ahern J, Lara-Saez I, Cutlar L, Zhou D, Murillas R, Larcher F, Wang W. 834 CRISPR/Cas9 based COL7A1 genomic editing in recessive dystrophic epidermolysis bullosa (RDEB) via non-viral polymer delivery system. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
138
|
Schmitt FC, Curry DJ, Zhou D, Stefan H. Minimal-invasive, ablative surgery - Potential and limitations for a curative treatment approach in epilepsy. Epilepsy Res 2018; 142:106-108. [PMID: 29622370 DOI: 10.1016/j.eplepsyres.2018.03.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
139
|
|
140
|
Acharya S, Adamová D, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad N, Ahn SU, Aiola S, Akindinov A, Alam SN, Alba JLB, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfaro Molina R, Alici A, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Alves Garcia Prado C, Andrei C, Andreou D, Andrews HA, Andronic A, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Anwar R, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arnold OW, Arsene IC, Arslandok M, Audurier B, Augustinus A, Averbeck R, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldisseri A, Ball M, Baral RC, Barbano AM, Barbera R, Barile F, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Barth K, Bartsch E, Basile M, Bastid N, Basu S, Batigne G, Batyunya B, Batzing PC, Bearden IG, Beck H, Bedda C, Behera NK, Belikov I, Bellini F, Bello Martinez H, Bellwied R, Beltran LGE, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Betev L, Bhasin A, Bhat IR, Bhati AK, Bhattacharjee B, Bhom J, Bianchi L, Bianchi N, Bianchin C, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boldizsár L, Bombara M, Bonomi G, Bonora M, Book J, Borel H, Borissov A, Borri M, Botta E, Bourjau C, Bratrud L, Braun-Munzinger P, Bregant M, Broker TA, Broz M, Brucken EJ, Bruna E, Bruno GE, Budnikov D, Buesching H, Bufalino S, Buhler P, Buncic P, Busch O, Buthelezi Z, Butt JB, Buxton JT, Cabala J, Caffarri D, Caines H, Caliva A, Calvo Villar E, Camerini P, Capon AA, Carena F, Carena W, Carnesecchi F, Castillo Castellanos J, Castro AJ, Casula EAR, Ceballos Sanchez C, Cerello P, Chandra S, Chang B, Chapeland S, Chartier M, Charvet JL, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cherney M, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Choi K, Chojnacki M, Choudhury S, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Chung SU, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Connors ME, Contreras JG, Cormier TM, Corrales Morales Y, Cortés Maldonado I, Cortese P, Cosentino MR, Costa F, Costanza S, Crkovská J, Crochet P, Cuautle E, Cunqueiro L, Dahms T, Dainese A, Danisch MC, Danu A, Das D, Das I, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Conti C, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Souza RD, Degenhardt HF, Deisting A, Deloff A, Deplano C, Dhankher P, Di Bari D, Di Mauro A, Di Nezza P, Di Ruzza B, Diaz Corchero MA, Dietel T, Dillenseger P, Divià R, Djuvsland Ø, Dobrin A, Domenicis Gimenez D, Dönigus B, Dordic O, Doremalen LVV, Dubey AK, Dubla A, Ducroux L, Duggal AK, Dupieux P, Ehlers RJ, Elia D, Endress E, Engel H, Epple E, Erazmus B, Erhardt F, Espagnon B, Esumi S, Eulisse G, Eum J, Evans D, Evdokimov S, Fabbietti L, Faivre J, Fantoni A, Fasel M, Feldkamp L, Feliciello A, Feofilov G, Ferencei J, Fernández Téllez A, Ferreiro EG, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Figueredo MAS, Filchagin S, Finogeev D, Fionda FM, Fiore EM, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Francescon A, Francisco A, Frankenfeld U, Fronze GG, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gajdosova K, Gallio M, Galvan CD, Ganoti P, Gao C, Garabatos C, Garcia-Solis E, Garg K, Gargiulo C, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Gianotti P, Giubellino P, Giubilato P, Gladysz-Dziadus E, Glässel P, Goméz Coral DM, Gomez Ramirez A, Gonzalez AS, Gonzalez V, González-Zamora P, Gorbunov S, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Grion N, Gronefeld JM, Grosa F, Grosse-Oetringhaus JF, Grosso R, Gruber L, Guber F, Guernane R, Guerzoni B, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Hadjidakis C, Hamagaki H, Hamar G, Hamon JC, Haque MR, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Herrera Corral G, Herrmann F, Hess BA, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hladky J, Hohlweger B, Horak D, Hornung S, Hosokawa R, Hristov P, Hughes C, Humanic TJ, Hussain N, Hussain T, Hutter D, Hwang DS, Iga Buitron SA, Ilkaev R, Inaba M, Ippolitov M, Irfan M, Isakov V, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadhav MB, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Jayarathna PHSY, Jena C, Jena S, Jercic M, Jimenez Bustamante RT, Jones PG, Jusko A, Kalinak P, Kalweit A, Kang JH, Kaplin V, Kar S, Karasu Uysal A, Karavichev O, Karavicheva T, Karayan L, Karczmarczyk P, Karpechev E, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan P, Khan SA, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kielbowicz MM, Kileng B, Kim B, Kim D, Kim DJ, Kim H, Kim JS, Kim J, Kim M, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kiss G, Klay JL, Klein C, Klein J, Klein-Bösing C, Klewin S, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Kofarago M, Kollegger T, Kolojvari A, Kondratiev V, Kondratyeva N, Kondratyuk E, Konevskikh A, Konyushikhin M, Kopcik M, Kour M, Kouzinopoulos C, Kovalenko O, Kovalenko V, Kowalski M, Koyithatta Meethaleveedu G, Králik I, Kravčáková A, Krivda M, Krizek F, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar A, Kumar J, Kumar L, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kweon MJ, Kwon Y, La Pointe SL, La Rocca P, Lagana Fernandes C, Lai YS, Lakomov I, Langoy R, Lapidus K, Lara C, Lardeux A, Lattuca A, Laudi E, Lavicka R, Lazaridis L, Lea R, Leardini L, Lee S, Lehas F, Lehner S, Lehrbach J, Lemmon RC, Lenti V, Leogrande E, León Monzón I, Lévai P, Li S, Li X, Lien J, Lietava R, Lim B, Lindal S, Lindenstruth V, Lindsay SW, Lippmann C, Lisa MA, Litichevskyi V, Ljunggren HM, Llope WJ, Lodato DF, Loenne PI, Loginov V, Loizides C, Loncar P, Lopez X, López Torres E, Lowe A, Luettig P, Luhder JR, Lunardon M, Luparello G, Lupi M, Lutz TH, Maevskaya A, Mager M, Mahajan S, Mahmood SM, Maire A, Majka RD, Malaev M, Malinina L, Mal'Kevich D, Malzacher P, Mamonov A, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Margutti J, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JAL, Martínez MI, Martínez García G, Martinez Pedreira M, Mas A, Masciocchi S, Masera M, Masoni A, Masson E, Mastroserio A, Mathis AM, Matyja A, Mayer C, Mazer J, Mazzilli M, Mazzoni MA, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Mercado Pérez J, Meres M, Mhlanga S, Miake Y, Mieskolainen MM, Mihaylov D, Mihaylov DL, Mikhaylov K, Milano L, Milosevic J, Mischke A, Mishra AN, Miśkowiec D, Mitra J, Mitu CM, Mohammadi N, Mohanty B, Mohisin Khan M, Montes E, Moreira De Godoy DA, Moreno LAP, Moretto S, Morreale A, Morsch A, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mukherjee M, Mulligan JD, Munhoz MG, Münning K, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Narayan A, Naru MU, Natal da Luz H, Nattrass C, Navarro SR, Nayak K, Nayak R, Nayak TK, Nazarenko S, Nedosekin A, Negrao De Oliveira RA, Nellen L, Nesbo SV, Ng F, Nicassio M, Niculescu M, Niedziela J, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Nobuhiro A, Noferini F, Nomokonov P, Nooren G, Noris JCC, Norman J, Nyanin A, Nystrand J, Oeschler H, Oh S, Ohlson A, Okubo T, Olah L, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onderwaater J, Oppedisano C, Orava R, Oravec M, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Pagano D, Pagano P, Paić G, Palni P, Pan J, Pandey AK, Panebianco S, Papikyan V, Pappalardo GS, Pareek P, Park J, Parmar S, Passfeld A, Pathak SP, Paticchio V, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez Lezama E, Peskov V, Pestov Y, Petráček V, Petrov V, Petrovici M, Petta C, Pezzi RP, Piano S, Pikna M, Pillot P, Pimentel LODL, Pinazza O, Pinsky L, Piyarathna DB, Płoskoń M, Planinic M, Pliquett F, Pluta J, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polichtchouk B, Poljak N, Poonsawat W, Pop A, Poppenborg H, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Puddu G, Pujahari P, Punin V, Putschke J, Rachevski A, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Rana DB, Raniwala R, Raniwala S, Räsänen SS, Rascanu BT, Rathee D, Ratza V, Ravasenga I, Read KF, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Reolon AR, Reshetin A, Reygers K, Riabov V, Ricci RA, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogochaya E, Rohr D, Röhrich D, Rokita PS, Ronchetti F, Rosas ED, Rosnet P, Rossi A, Rotondi A, Roukoutakis F, Roy A, Roy C, Roy P, Rubio Montero AJ, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Saarinen S, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahlmuller B, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Saleh MA, Salzwedel J, Sambyal S, Samsonov V, Sandoval A, Sarkar D, Sarkar N, Sarma P, Sas MHP, Scapparone E, Scarlassara F, Scharenberg RP, Scheid HS, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schuchmann S, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Scott R, Šefčík M, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senosi K, Senyukov S, Serradilla E, Sett P, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma M, Sharma M, Sharma N, Sheikh AI, Shigaki K, Shou Q, Shtejer K, Sibiriak Y, Siddhanta S, Sielewicz KM, Siemiarczuk T, Silvermyr D, Silvestre C, Simatovic G, Simonetti G, Singaraju R, Singh R, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Snellman TW, Song J, Song M, Soramel F, Sorensen S, Sozzi F, Spiriti E, Sputowska I, Srivastava BK, Stachel J, Stan I, Stankus P, Stenlund E, Stocco D, Storetvedt MM, Strmen P, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumowidagdo S, Suzuki K, Swain S, Szabo A, Szarka I, Tabassam U, Takahashi J, Tambave GJ, Tanaka N, Tarhini M, Tariq M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terasaki K, Terrevoli C, Teyssier B, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Tripathy S, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzeciak BA, Tsuji T, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Utrobicic A, Vala M, Van Der Maarel J, Van Hoorne JW, van Leeuwen M, Vanat T, Vande Vyvre P, Varga D, Vargas A, Vargyas M, Varma R, Vasileiou M, Vasiliev A, Vauthier A, Vázquez Doce O, Vechernin V, Veen AM, Velure A, Vercellin E, Vergara Limón S, Vernet R, Vértesi R, Vickovic L, Vigolo S, Viinikainen J, Vilakazi Z, Villalobos Baillie O, Villatoro Tello A, Vinogradov A, Vinogradov L, Virgili T, Vislavicius V, Vodopyanov A, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vranic D, Vrláková J, Wagner B, Wang H, Wang M, Watanabe D, Watanabe Y, Weber M, Weber SG, Weiser DF, Wenzel SC, Wessels JP, Westerhoff U, Whitehead AM, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Williams MCS, Willsher E, Windelband B, Witt WE, Yalcin S, Yamakawa K, Yang P, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang H, Zhang X, Zhang Y, Zhang C, Zhang Z, Zhao C, Zhigareva N, Zhou D, Zhou Y, Zhou Z, Zhu H, Zhu J, Zhu X, Zichichi A, Zimmermann A, Zimmermann MB, Zinovjev G, Zmeskal J, Zou S. D-Meson Azimuthal Anisotropy in Midcentral Pb-Pb Collisions at sqrt[s]_{NN}=5.02 TeV. PHYSICAL REVIEW LETTERS 2018; 120:102301. [PMID: 29570314 DOI: 10.1103/physrevlett.120.102301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2017] [Revised: 11/16/2017] [Indexed: 06/08/2023]
Abstract
The azimuthal anisotropy coefficient v_{2} of prompt D^{0}, D^{+}, D^{*+}, and D_{s}^{+} mesons was measured in midcentral (30%-50% centrality class) Pb-Pb collisions at a center-of-mass energy per nucleon pair sqrt[s_{NN}]=5.02 TeV, with the ALICE detector at the LHC. The D mesons were reconstructed via their hadronic decays at midrapidity, |y|<0.8, in the transverse momentum interval 1<p_{T}<24 GeV/c. The measured D-meson v_{2} has similar values as that of charged pions. The D_{s}^{+} v_{2}, measured for the first time, is found to be compatible with that of nonstrange D mesons. The measurements are compared with theoretical calculations of charm-quark transport in a hydrodynamically expanding medium and have the potential to constrain medium parameters.
Collapse
|
141
|
Bui K, Zhou D, Xu H, Floettmann E, Al-Huniti N. Clinical Pharmacokinetics and Pharmacodynamics of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist. Clin Pharmacokinet 2018; 56:573-582. [PMID: 28035588 DOI: 10.1007/s40262-016-0479-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Naloxegol is a peripherally acting µ-opioid receptor antagonist approved for use as an orally administered tablet (therapeutic doses of 12.5 and 25 mg) for the treatment of opioid-induced constipation. Over a wide dose range (i.e. single supratherapeutic doses up to 1000 mg in healthy volunteers), the pharmacokinetic properties of naloxegol appear to be time- and dose-independent. Naloxegol is rapidly absorbed, with mean time to maximum plasma concentration of <2 h. Following once-daily administration, steady state is achieved within 2-3 days and minimal accumulation is observed. The primary route of naloxegol elimination is via hepatic metabolism, with renal excretion playing a minimal role. In clinical studies, six metabolites were found in feces, urine or plasma, none of which have been identified as unique or disproportionate human metabolites. The major plasma circulating species is naloxegol. There are small effects of mild and moderate renal impairment, age, race, and body mass index on the systemic exposure of naloxegol; however, gender has no effect on the pharmacokinetics of this agent. Naloxegol is a sensitive substrate of cytochrome P450 (CYP) 3A4 and its exposure can be significantly altered by strong or moderate CYP3A modulators. Food increases the bioavailability of naloxegol, and the relative bioavailability of the tablet formulation was not limited by dissolution. Naloxegol in the dose range of 8-125 mg can antagonize morphine-induced peripheral effects without impacting the effect of morphine on the central nervous system, consistent with a peripheral mode of action.
Collapse
|
142
|
Li Z, Zou HY, Zhou D. The full-length sequence of the HLA-C allele, HLA-C*15:13:01:01. HLA 2018; 91:216-220. [PMID: 29316312 DOI: 10.1111/tan.13208] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Revised: 01/03/2018] [Accepted: 01/04/2018] [Indexed: 11/28/2022]
Abstract
Confirmed the full-length sequence of HLA-C*15:13:01:01 by cloning and sequencing in a Chinese donor.
Collapse
|
143
|
Liu W, Hu X, An D, Gong Q, Zhou D. Disrupted intrinsic and remote functional connectivity in heterotopia-related epilepsy. Acta Neurol Scand 2018; 137:109-116. [PMID: 28875535 DOI: 10.1111/ane.12831] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/17/2017] [Indexed: 02/05/2023]
Abstract
OBJECTIVES Several neuroimaging studies have examined neural interactions in patients with periventricular nodular heterotopia (PNH). However, features of the underlying functional network remain poorly understood. In this study, we examined alterations in the local (regional) and remote (interregional) cerebral networks in this disorder. METHODS Twenty-eight subjects all having suffered from PNH with epilepsy, as well as 28 age- and sex- matched healthy controls, were enrolled in this study. Amplitude of low-frequency fluctuation (ALFF) and seed-based functional connectivity (FC) were calculated to detect regional neural function and functional network integration, respectively. RESULTS Compared with healthy controls, patients with PNH-related epilepsy showed decreased ALFF in the ventromedial prefrontal cortex (vmPFC) and precuneus areas. ALFF values in both areas were negative correlated with epilepsy duration (P < .05, Bonferroni-corrected). Furthermore, patients with PNH-related epilepsy had increased remote interregional FC mainly in bilateral prefrontal and parietal cortices, supramarginal gyrus, dorsal cingulate gyrus, and right insula; lower FC was found in posterior brain regions including bilateral parahippocampal gyrus and inferior temporal gyrus. CONCLUSIONS Focal spontaneous hypofunction, as assessed by ALFF, correlates with epilepsy duration in patients with PNH-related epilepsy. Abnormalities existed both within the default-mode network and then across the whole brain, demonstrating that intrinsic brain dysfunction may be related to specific network interactions. Our findings provide novel understanding of the connectivity-based pathophysiological mechanisms of PNH.
Collapse
|
144
|
Xueting L, Rehman MU, Zhang H, Tian X, Wu X, Mehmood K, Zhou D. Protective effects of Nano-elemental selenium against chromium-vi-induced oxidative stress in broiler liver. J BIOL REG HOMEOS AG 2018; 32:47-54. [PMID: 29504364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The valuable role of selenium in mitigation of oxidative stress and heavy metal toxicity is well-known. Thus, the aim of the current study on broiler chickens was to examine whether nano elemental selenium (Nano-Se) supplementation can reduce the effects of chromium VI (K2Cr2O7) toxicity. For this purpose, a total of 150, one-day-old broiler chickens were allotted to five groups with three replicates: control group (standard diet), poisoned group (K2Cr2O7 via drinking water), protection group (K2Cr2O7 + Nano- Se), cure group (K2Cr2O7 for initial 2 weeks and then Nano-Se), and prevention group (opposite to the cure group). The broilers were detected by the activities of marker enzymes and oxidative stress markers including, aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT) and superoxide dismutase (SOD), glutathione peroxidase (GSH-px), malondialdehyde (MDA), respectively. The (K2Cr2O7 administration caused histopathological damage in the liver of the chickens. Moreover, changes in serum biochemical indicators and oxidative stress parameters were also observed. Nano-Se supplementation increased the levels of GSH-px but reduced the activities of SOD, MDA, GGT, ALT and AST in the experimental groups (P less than 0.05). Our results showed that Nano-Se plays a protective role by preventing the oxidative stress induced by the chromium VI in broiler chickens.
Collapse
|
145
|
Zhou M, Li L, Zhang Q, Ma S, Sun J, Zhu L, Lu D, Zhu J, Zhou D, Zheng Y, Yang X, Xie M, Zhu M, Ye X, Xie W. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. QJM 2018; 111:23-31. [PMID: 29025045 DOI: 10.1093/qjmed/hcx183] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hemophagocytic lymphohistiocytosis (HLH) is a rare clinical syndrome characterized by an infrequent but immune-mediated life-threatening disease, with confusing clinical manifestations, rapidly deteriorating health, high morbidity and mortality and challenging diagnosis. AIM The purpose of this study was to improve the recognition and understanding of HLH. DESIGN Retrospective observational cross-sectional study. METHODS Data were collected for all cases of adult patients diagnosed with HLH in a large cohort managed at a single medical center from January 2011 to December 2015. RESULTS The median age was 52 years (range 18-90 years) and 123 (60.0%) were male. Over 95% patients manifested fever, hyperferritinemia and elevated lactate dehydrogenase. Underlying triggers of HLH were as follows: 119 (58.0%) malignancies, 83 (40.5%) infections, 14 (6.8%) unknown triggers and 14 (6.8%) autoimmune disorders. The median overall survival was 55 days. And elderly patients (age ≥60 years) had a markedly worse survival compared with young patients (age <60 years) (median overall survival 24 days vs. 159 days, respectively; P <0.001). In a multivariable analysis, platelet <40 × 109/l (HR = 2.534; 95% CI 1.152-5.573; P = 0.021), PT prolonged >3 s (HR = 1.909; 95% CI 1.127-3.234; P = 0.016) and malignancy (HR = 1.614; 95% CI 1.008-2.582; P = 0.046) were correlated with poor survival. CONCLUSION HLH adult patients had very complex clinical manifestations as well as underlying diseases. Patients with PLT <40 ×109/l, PT prolonged >3 s and malignancy had inferior survival. It is of great importance to improve our understanding of this syndrome.
Collapse
|
146
|
Zhou D, Wang Z, Li M, Xing M, Xian T, Tu K. Carvacrol and eugenol effectively inhibitRhizopus stoloniferand control postharvest soft rot decay in peaches. J Appl Microbiol 2017; 124:166-178. [DOI: 10.1111/jam.13612] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 09/16/2017] [Accepted: 10/09/2017] [Indexed: 11/28/2022]
|
147
|
Acharya S, Adamová D, Adolfsson J, Aggarwal MM, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahn SU, Aiola S, Akindinov A, Al-Turany M, Alam SN, Albuquerque DSD, Aleksandrov D, Alessandro B, Alfaro Molina R, Ali Y, Alici A, Alkin A, Alme J, Alt T, Altenkamper L, Altsybeev I, Alves Garcia Prado C, Andrei C, Andreou D, Andrews HA, Andronic A, Anguelov V, Anson C, Antičić T, Antinori F, Antonioli P, Anwar R, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arnold OW, Arsene IC, Arslandok M, Audurier B, Augustinus A, Averbeck R, Azmi MD, Badalà A, Baek YW, Bagnasco S, Bailhache R, Bala R, Baldisseri A, Ball M, Baral RC, Barbano AM, Barbera R, Barile F, Barioglio L, Barnaföldi GG, Barnby LS, Barret V, Bartalini P, Barth K, Bartsch E, Bastid N, Basu S, Batigne G, Batyunya B, Batzing PC, Bazo Alba JL, Bearden IG, Beck H, Bedda C, Behera NK, Belikov I, Bellini F, Bello Martinez H, Bellwied R, Beltran LGE, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berenyi D, Bertens RA, Berzano D, Betev L, Bhasin A, Bhat IR, Bhattacharjee B, Bhom J, Bianchi A, Bianchi L, Bianchi N, Bianchin C, Bielčík J, Bielčíková J, Bilandzic A, Biro G, Biswas R, Biswas S, Blair JT, Blau D, Blume C, Boca G, Bock F, Bogdanov A, Boldizsár L, Bombara M, Bonomi G, Bonora M, Book J, Borel H, Borissov A, Borri M, Botta E, Bourjau C, Bratrud L, Braun-Munzinger P, Bregant M, Broker TA, Broz M, Brucken EJ, Bruna E, Bruno GE, Budnikov D, Buesching H, Bufalino S, Buhler P, Buncic P, Busch O, Buthelezi Z, Butt JB, Buxton JT, Cabala J, Caffarri D, Caines H, Caliva A, Calvo Villar E, Camerini P, Capon AA, Carena F, Carena W, Carnesecchi F, Castillo Castellanos J, Castro AJ, Casula EAR, Ceballos Sanchez C, Chandra S, Chang B, Chang W, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chauvin A, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato DD, Cho S, Chochula P, Chojnacki M, Choudhury S, Chowdhury T, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Chung SU, Cicalo C, Cifarelli L, Cindolo F, Cleymans J, Colamaria F, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contreras JG, Cormier TM, Corrales Morales Y, Cortés Maldonado I, Cortese P, Cosentino MR, Costa F, Costanza S, Crkovská J, Crochet P, Cuautle E, Cunqueiro L, Dahms T, Dainese A, Danisch MC, Danu A, Das D, Das I, Das S, Dash A, Dash S, De S, De Caro A, de Cataldo G, de Conti C, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Pasquale S, De Souza RD, Degenhardt HF, Deisting A, Deloff A, Deplano C, Dhankher P, Di Bari D, Di Mauro A, Di Nezza P, Di Ruzza B, Diaz Corchero MA, Dietel T, Dillenseger P, Ding Y, Divià R, Djuvsland Ø, Dobrin A, Domenicis Gimenez D, Dönigus B, Dordic O, Doremalen LVR, Dubey AK, Dubla A, Ducroux L, Dudi S, Duggal AK, Dukhishyam M, Dupieux P, Ehlers RJ, Elia D, Endress E, Engel H, Epple E, Erazmus B, Erhardt F, Espagnon B, Eulisse G, Eum J, Evans D, Evdokimov S, Fabbietti L, Faivre J, Fantoni A, Fasel M, Feldkamp L, Feliciello A, Feofilov G, Fernández Téllez A, Ferreiro EG, Ferretti A, Festanti A, Feuillard VJG, Figiel J, Figueredo MAS, Filchagin S, Finogeev D, Fionda FM, Floris M, Foertsch S, Foka P, Fokin S, Fragiacomo E, Francescon A, Francisco A, Frankenfeld U, Fronze GG, Fuchs U, Furget C, Furs A, Fusco Girard M, Gaardhøje JJ, Gagliardi M, Gago AM, Gajdosova K, Gallio M, Galvan CD, Ganoti P, Garabatos C, Garcia-Solis E, Garg K, Gargiulo C, Gasik P, Gauger EF, Gay Ducati MB, Germain M, Ghosh J, Ghosh P, Ghosh SK, Gianotti P, Giubellino P, Giubilato P, Gladysz-Dziadus E, Glässel P, Goméz Coral DM, Gomez Ramirez A, Gonzalez AS, Gonzalez V, González-Zamora P, Gorbunov S, Görlich L, Gotovac S, Grabski V, Graczykowski LK, Graham KL, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan A, Grigoryan S, Gronefeld JM, Grosa F, Grosse-Oetringhaus JF, Grosso R, Guber F, Guernane R, Guerzoni B, Gulbrandsen K, Gunji T, Gupta A, Gupta R, Guzman IB, Haake R, Hadjidakis C, Hamagaki H, Hamar G, Hamon JC, Haque MR, Harris JW, Harton A, Hassan H, Hatzifotiadou D, Hayashi S, Heckel ST, Hellbär E, Helstrup H, Herghelegiu A, Hernandez EG, Herrera Corral G, Herrmann F, Hess BA, Hetland KF, Hillemanns H, Hills C, Hippolyte B, Hohlweger B, Horak D, Hornung S, Hosokawa R, Hristov P, Hughes C, Humanic TJ, Hussain N, Hussain T, Hutter D, Hwang DS, Iga Buitron SA, Ilkaev R, Inaba M, Ippolitov M, Islam MS, Ivanov M, Ivanov V, Izucheev V, Jacak B, Jacazio N, Jacobs PM, Jadhav MB, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Jayarathna PHSY, Jena C, Jercic M, Jimenez Bustamante RT, Jones PG, Jusko A, Kalinak P, Kalweit A, Kang JH, Kaplin V, Kar S, Karasu Uysal A, Karavichev O, Karavicheva T, Karayan L, Karczmarczyk P, Karpechev E, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khabanova Z, Khan P, Khan SA, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kielbowicz MM, Kileng B, Kim B, Kim D, Kim DJ, Kim H, Kim JS, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kiss G, Klay JL, Klein C, Klein J, Klein-Bösing C, Klewin S, Kluge A, Knichel ML, Knospe AG, Kobdaj C, Kofarago M, Köhler MK, Kollegger T, Kondratiev V, Kondratyeva N, Kondratyuk E, Konevskikh A, Konyushikhin M, Kopcik M, Kour M, Kouzinopoulos C, Kovalenko O, Kovalenko V, Kowalski M, Koyithatta Meethaleveedu G, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Kryshen E, Krzewicki M, Kubera AM, Kučera V, Kuhn C, Kuijer PG, Kumar A, Kumar J, Kumar L, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kweon MJ, Kwon Y, La Pointe SL, La Rocca P, Lagana Fernandes C, Lai YS, Lakomov I, Langoy R, Lapidus K, Lara C, Lardeux A, Lattuca A, Laudi E, Lavicka R, Lea R, Leardini L, Lee S, Lehas F, Lehner S, Lehrbach J, Lemmon RC, Leogrande E, León Monzón I, Lévai P, Li X, Lien J, Lietava R, Lim B, Lindal S, Lindenstruth V, Lindsay SW, Lippmann C, Lisa MA, Litichevskyi V, Llope WJ, Lodato DF, Loenne PI, Loginov V, Loizides C, Loncar P, Lopez X, López Torres E, Lowe A, Luettig P, Luhder JR, Lunardon M, Luparello G, Lupi M, Lutz TH, Maevskaya A, Mager M, Mahmood SM, Maire A, Majka RD, Malaev M, Malinina L, Mal'Kevich D, Malzacher P, Mamonov A, Manko V, Manso F, Manzari V, Mao Y, Marchisone M, Mareš J, Margagliotti GV, Margotti A, Margutti J, Marín A, Markert C, Marquard M, Martin NA, Martinengo P, Martinez JAL, Martínez MI, Martínez García G, Martinez Pedreira M, Masciocchi S, Masera M, Masoni A, Masson E, Mastroserio A, Mathis AM, Matuoka PFT, Matyja A, Mayer C, Mazer J, Mazzilli M, Mazzoni MA, Meddi F, Melikyan Y, Menchaca-Rocha A, Meninno E, Mercado Pérez J, Meres M, Mhlanga S, Miake Y, Mieskolainen MM, Mihaylov DL, Mikhaylov K, Mischke A, Mishra AN, Miśkowiec D, Mitra J, Mitu CM, Mohammadi N, Mohanty AP, Mohanty B, Mohisin Khan M, Montes E, Moreira De Godoy DA, Moreno LAP, Moretto S, Morreale A, Morsch A, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mukherjee M, Mulligan JD, Munhoz MG, Münning K, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myers CJ, Myrcha JW, Nag D, Naik B, Nair R, Nandi BK, Nania R, Nappi E, Narayan A, Naru MU, Natal da Luz H, Nattrass C, Navarro SR, Nayak K, Nayak R, Nayak TK, Nazarenko S, Negrao De Oliveira RA, Nellen L, Nesbo SV, Ng F, Nicassio M, Niculescu M, Niedziela J, Nielsen BS, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Nomokonov P, Nooren G, Noris JCC, Norman J, Nyanin A, Nystrand J, Oeschler H, Ohlson A, Okubo T, Olah L, Oleniacz J, Oliveira Da Silva AC, Oliver MH, Onderwaater J, Oppedisano C, Orava R, Oravec M, Ortiz Velasquez A, Oskarsson A, Otwinowski J, Oyama K, Pachmayer Y, Pacik V, Pagano D, Paić G, Palni P, Pan J, Pandey AK, Panebianco S, Papikyan V, Pareek P, Park J, Parmar S, Passfeld A, Pathak SP, Patra RN, Paul B, Pei H, Peitzmann T, Peng X, Pereira LG, Pereira Da Costa H, Peresunko D, Perez Lezama E, Peskov V, Pestov Y, Petráček V, Petrov V, Petrovici M, Petta C, Pezzi RP, Piano S, Pikna M, Pillot P, Pimentel LODL, Pinazza O, Pinsky L, Piyarathna DB, Płoskoń M, Planinic M, Pliquett F, Pluta J, Pochybova S, Podesta-Lerma PLM, Poghosyan MG, Polichtchouk B, Poljak N, Poonsawat W, Pop A, Poppenborg H, Porteboeuf-Houssais S, Pozdniakov V, Prasad SK, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Punin V, Putschke J, Raha S, Rajput S, Rak J, Rakotozafindrabe A, Ramello L, Rami F, Rana DB, Raniwala R, Raniwala S, Räsänen SS, Rascanu BT, Rathee D, Ratza V, Ravasenga I, Read KF, Redlich K, Rehman A, Reichelt P, Reidt F, Ren X, Renfordt R, Reshetin A, Reygers K, Riabov V, Richert T, Richter M, Riedler P, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogochaya E, Rohr D, Röhrich D, Rokita PS, Ronchetti F, Rosas ED, Rosnet P, Rossi A, Rotondi A, Roukoutakis F, Roy C, Roy P, Rubio Montero AJ, Rueda OV, Rui R, Rumyantsev B, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Saarinen S, Sadhu S, Sadovsky S, Šafařík K, Saha SK, Sahlmuller B, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu PK, Saini J, Sakai S, Saleh MA, Salzwedel J, Sambyal S, Samsonov V, Sandoval A, Sarkar A, Sarkar D, Sarkar N, Sarma P, Sas MHP, Scapparone E, Scarlassara F, Schaefer B, Scheid HS, Schiaua C, Schicker R, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schukraft J, Schutz Y, Schwarz K, Schweda K, Scioli G, Scomparin E, Šefčík M, Seger JE, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senosi K, Senyukov S, Serradilla E, Sett P, Sevcenco A, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma A, Sharma M, Sharma M, Sharma N, Sheikh AI, Shigaki K, Shirinkin S, Shou Q, Shtejer K, Sibiriak Y, Siddhanta S, Sielewicz KM, Siemiarczuk T, Silaeva S, Silvermyr D, Simatovic G, Simonetti G, Singaraju R, Singh R, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Slupecki M, Smirnov N, Snellings RJM, Snellman TW, Song J, Song M, Soramel F, Sorensen S, Sozzi F, Sputowska I, Stachel J, Stan I, Stankus P, Stenlund E, Stocco D, Storetvedt MM, Strmen P, Suaide AAP, Sugitate T, Suire C, Suleymanov M, Suljic M, Sultanov R, Šumbera M, Sumowidagdo S, Suzuki K, Swain S, Szabo A, Szarka I, Tabassam U, Takahashi J, Tambave GJ, Tanaka N, Tarhini M, Tariq M, Tarzila MG, Tauro A, Tejeda Muñoz G, Telesca A, Terasaki K, Terrevoli C, Teyssier B, Thakur D, Thakur S, Thomas D, Thoresen F, Tieulent R, Tikhonov A, Timmins AR, Toia A, Toppi M, Torres SR, Tripathy S, Trogolo S, Trombetta G, Tropp L, Trubnikov V, Trzaska WH, Trzeciak BA, Tsuji T, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Umaka EN, Uras A, Usai GL, Utrobicic A, Vala M, Van Der Maarel J, Van Hoorne JW, van Leeuwen M, Vanat T, Vande Vyvre P, Varga D, Vargas A, Vargyas M, Varma R, Vasileiou M, Vasiliev A, Vauthier A, Vázquez Doce O, Vechernin V, Veen AM, Velure A, Vercellin E, Vergara Limón S, Vernet R, Vértesi R, Vickovic L, Vigolo S, Viinikainen J, Vilakazi Z, Villalobos Baillie O, Villatoro Tello A, Vinogradov A, Vinogradov L, Virgili T, Vislavicius V, Vodopyanov A, Völkl MA, Voloshin K, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Voscek D, Vranic D, Vrláková J, Wagner B, Wang H, Wang M, Watanabe D, Watanabe Y, Weber M, Weber SG, Weiser DF, Wenzel SC, Wessels JP, Westerhoff U, Whitehead AM, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Williams MCS, Willsher E, Windelband B, Witt WE, Xu R, Yalcin S, Yamakawa K, Yang P, Yano S, Yin Z, Yokoyama H, Yoo IK, Yoon JH, Yun E, Yurchenko V, Zaccolo V, Zaman A, Zampolli C, Zanoli HJC, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zbroszczyk H, Zhalov M, Zhang H, Zhang X, Zhang Y, Zhang C, Zhang Z, Zhao C, Zhigareva N, Zhou D, Zhou Y, Zhou Z, Zhu H, Zhu J, Zhu Y, Zichichi A, Zimmermann MB, Zinovjev G, Zmeskal J, Zou S. J/ψ Elliptic Flow in Pb-Pb Collisions at sqrt[s_{NN}]=5.02 TeV. PHYSICAL REVIEW LETTERS 2017; 119:242301. [PMID: 29286736 DOI: 10.1103/physrevlett.119.242301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Indexed: 06/07/2023]
Abstract
We report a precise measurement of the J/ψ elliptic flow in Pb-Pb collisions at sqrt[s_{NN}]=5.02 TeV with the ALICE detector at the LHC. The J/ψ mesons are reconstructed at midrapidity (|y|<0.9) in the dielectron decay channel and at forward rapidity (2.5<y<4.0) in the dimuon channel, both down to zero transverse momentum. At forward rapidity, the elliptic flow v_{2} of the J/ψ is studied as a function of the transverse momentum and centrality. A positive v_{2} is observed in the transverse momentum range 2<p_{T}<8 GeV/c in the three centrality classes studied and confirms with higher statistics our earlier results at sqrt[s_{NN}]=2.76 TeV in semicentral collisions. At midrapidity, the J/ψ v_{2} is investigated as a function of the transverse momentum in semicentral collisions and found to be in agreement with the measurements at forward rapidity. These results are compared to transport model calculations. The comparison supports the idea that at low p_{T} the elliptic flow of the J/ψ originates from the thermalization of charm quarks in the deconfined medium but suggests that additional mechanisms might be missing in the models.
Collapse
|
148
|
Zhou D, Meng R, Zhang X, Guo L, Li S, Wu W, Duan J, Song H, Ding Y, Ji X. Intracranial hypertension induced by internal jugular vein stenosis can be resolved by stenting. Eur J Neurol 2017; 25:365-e13. [PMID: 29114973 DOI: 10.1111/ene.13512] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 11/02/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND AND PURPOSE Idiopathic intracranial hypertension (IIH) is characterized by abnormally elevated intracranial pressure (ICP) without identifiable etiology. Recently, however, a subset of patients with presumed IIH have been found with isolated internal jugular vein (IJV) stenosis in the absence of intracranial abnormalities. METHODS Fifteen consecutive patients were screened from 46 patients suspected as IIH and were finally confirmed as isolated IJV stenosis. The stenotic IJV was corrected with stenting when the trans-stenotic mean pressure gradient (∆MPG) was equal to or higher than 5.44 cmH2 O. Dynamic magnetic resonance venography, computed tomographic venography and digital subtraction angiography of the IJV, ∆MPG, ICP, Headache Impact Test 6 and the Frisén papilledema grade score before and after stenting were compared. RESULTS All the stenotic IJVs were corrected by stenting. ∆MPG decreased and the abnormal collateral veins disappeared or shrank immediately. Headache, tinnitus, papilledema and ICP were significantly ameliorated at 14 ± 3 days of follow-up (all P < 0.01). At 12 ± 5.6 months of outpatient follow-up, headache disappeared in 14 out of 15 patients (93.3%), visual impairments were recovered in 10 of 12 patients (83.3%) and tinnitus resolved in 10 out of 11 patients (90.9%). In 12 out of 15 cases, the Frisén papilledema grade scores declined to 1 (0-2). The stented IJVs in all 15 patients kept to sufficient blood flows on computed tomographic venography follow-up without stenting-related adverse events. CONCLUSIONS Non-thrombotic IJV stenosis may be a potential etiology of IIH. Stenting seems to be a promising option to address the issue of intracranial hypertension from the etiological level, particularly after medical treatment failure.
Collapse
|
149
|
Tang SS, Liang ZY, Guo LR, Zhang JH, Zhou D. Proprotein convertase 1 mediated proneuropeptide proteolytic processing in ischemic neuron injury. ACTA ACUST UNITED AC 2017; 118:609-612. [PMID: 29198128 DOI: 10.4149/bll_2017_117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Pro-protein processing mechanism plays an important role in neuron injury. OBJECTIVE To study the protein convertase 1 (PC1) mediated processing mechanism, the ischemic cellular or tissue proPC1/PC1 or proCgA/CgA (pro-chromogranin A) was analyzed. METHODS NS20Y differentiated cells were stressed by 0-6 h of oxygen and glucose deprivation (OGD) in glucose-free DMEM and an anaerobic jar environment. Ischemic C57BL/J mouse model was established by performing 60-min of middle cerebral artery occlusion (MCAO) operation and subsequent 4 or 24-h reperfusion. The TUNEL, immunochemistry, and Western blot methods were used to detect protein expression in ischemic cells or tissues. RESULTS The OGD or MCAO stress caused substantial cell death in a dose-dependent manner (p < 0.05 or 0.01). With the increasing OGD dose, proPC1 and PC1 proteins gradually increased (p < 0.05 or 0.01) whereas proCgA and CgA proteins decreased (p < 0.05). In vivo the proPC1 and PC1 expressions presented with a peak at 4-h and then decreased at 24-h reperfusion (p < 0.05 or 0.01). The tissue proCgA and CgA proteins decreased with the increasing reperfusion time (p < 0.05). CONCLUSIONS The results suggest that the increasing PC1 expression promoted the transformation of proCgA into CgA or smaller peptides, i.e. Pancreastatin or Secretoneurin, and the PC1 mediated processing plays a critical role (Fig. 4, Ref. 15).
Collapse
|
150
|
Chi X, Zhou D. Risk factors for mortality in patients with anti-NMDA receptor encephalitis: Reply to comment on data sparsity. Acta Neurol Scand 2017; 136:738. [PMID: 29105077 DOI: 10.1111/ane.12791] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|